← Back to patent-cliff list
NST-1024
Tier C — Watch / tradeNST-1024
Northsea Therapeutics Bv
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CETP
Indications (approved)：Hypertriglyceridaemia
Regional status
US
Phase II
2023-06-30
EU
Phase I
2020-10-27
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NST-1024?
Approved indications include: Hypertriglyceridaemia.
When does the NST-1024 patent expire?
No public expiry year is available for NST-1024 yet; this page updates once verified.
How do I get a quote for NST-1024 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03